| Name | Title | Contact Details |
|---|
BabelBark is the most comprehensive pet health management tool available, managing pets care, records and fitness all in one place. The BabelBark mobile app for pet parents links with the software platforms for pet businesses, shelters and veterinarians to help pets live the happiest, healthiest lives possible—by connecting everyone who cares for them! Whether you love, treat, groom, train, walk or sit for pets—BabelBark helps you do it even better.
EG Life Sciences is a hybrid professional Life Sciences consulting services firm that provides Pharmaceutical, Biotechnology, and Medical device companies with the resources they need to meet the unique challenges of FDA regulated industries.
Compassus is a national leader in providing high-quality, compassionate, person-centered care to individuals wherever they call home. Our continuum of integrated home-based care, including home health infusion therapy palliative and hospice care ensures patients and their families have the support they need to address current and future health needs. Partnering with Compassus brings peace of mind to patients, caregivers, and health care providers. Our team members work collaboratively to manage patient conditions and meet goals of care alongside referring physicians, health systems, long-term care partners, and family members. Our value is in the compassion and expertise of our teams, which act as an extension of patients` existing care teams. We believe everyone who interacts with us should experience our individualized `Care for who` I am philosophy, from the care services we provide to patients and families to how we interact with our partners and one another.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
At Tomorrow Health, we believe you deserve an exceptional experience for care at home. That`s why we`re bringing together personal service and modern technology to get you the products and supplies you need, covered by your health insurance and delivered right to your door.